trans-Propenylpyrazin | 18217-80-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: trans-Propenylpyrazin
• 英文别名: 2-(trans-1-Propenyl)-pyrazin；propenyl-pyrazine；1-Propenylpyrazine；2-[(E)-prop-1-enyl]pyrazine
• CAS: 18217-80-6
• 化学式: C₇H₈N₂
• 分子量: 120.154
• InChiKey: ZBHYPERRXYKXGT-NSCUHMNNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• POTENT AND SELECTIVE INHIBITORS OF CYTOCHROME P450
  申请人：University of Kentucky Research Foundation

  公开号：US20210246109A1

  公开（公告）日：2021-08-12

  Inhibitors of the enzyme cytochrome P450 (CYP), including 1B1 (CYP1B1), 1A1 (CYP1A1) and 19A1 (CYP19A1) are provided, and are useful in medical applications. Disclosed are highly potent and selective compounds that can be used in chemoprevention to ameliorate malignant changes induced by CYP, or to aid in treatment, including restoration of chemotherapeutic efficacy.

  本文提供了细胞色素P450 (CYP) 酶的抑制剂，包括1B1 (CYP1B1)，1A1 (CYP1A1) 和19A1 (CYP19A1)，这些抑制剂在医学应用中非常有用。本文还披露了高效、选择性的化合物，可用于化学预防，以减轻CYP引起的恶性变化，或用于治疗，包括恢复化疗的疗效。
• UV EMITTERS COMPRISING A MULTIPLE BOND
  申请人：MERCK PATENT GMBH

  公开号：US20150340612A1

  公开（公告）日：2015-11-26

  The invention relates to organic electroluminescent devices comprising organic compounds with a double or triple bond, to which at least one aromatic ring is bonded, as emitter compounds. The invention also relates to possible uses of said devices.

  本发明涉及含有双键或三键的有机化合物作为发光化合物，其中至少一个芳香环与之键合的有机电致发光器件。本发明还涉及所述器件的可能用途。
• Chemosensory receptor ligand-based therapies
  申请人：Anji Pharma (US) LLC

  公开号：US10610500B2

  公开（公告）日：2020-04-07

  Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

  本文提供了通过施用包含化感受体配体（如苦味受体配体）的组合物来治疗与化感受体相关的病症（包括糖尿病、肥胖症和其他代谢性疾病、失调或病症）的方法。本文还提供了化学感觉受体配体组合物，包括苦味受体配体组合物，及其用于本发明方法的制备方法。本文还提供了包含二甲双胍及其盐类的组合物和使用方法。
• CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES
  申请人：Anji Pharma (US) LLC

  公开号：EP2661266B1

  公开（公告）日：2020-09-16
• PROCESS FOR PRODUCING A LIQUID EXTRACT, PROCESS FOR PRODUCING COFFEE WITH REDUCED BITTERNESS, PROCESS FOR PRODUCING TEA, AND PROCESS FOR PRODUCING A LIQUID EXTRACT WHICH INCLUDE PYRAZINES
  申请人：The Coca-Cola Company

  公开号：EP3297450A1

  公开（公告）日：2018-03-28